Mountain View, CA (openPR) 30 September 2010 –

Cellect, Inc., a contract service provider that specializes in biotechnology to identify genetic screening for new therapeutic targets, has a contract for nine months with the National Cancer Institute (NCI) in technology companies RNAi use screening to identify synthetic lethal gene in breast cancer cells.

is considerable interest in cancer research is to identify and use combinations of genes that do not individually disrupted in cancer cells, but the combined results of suppression of cell death. This synergistic effect of block two genes is the basis for the development of new classes of therapies with low toxicity. However, approaching the complexity of these combinatorial interactions that make them particularly difficult to identify by screening dressed. Cellect test with pooled shRNA Lentiviral Libraries suppressor gene that can be easily adapted to combinatorial screens provide a unique approach to the practices of this synthetic lethal genetic interactions identified.

“We are very pleased to start this project and already have several hundred to several DNA damage repair genes and we selected in this screening test,” said CEO Dr. Alex Cellect Chenchik. “If successful, this will be the first approach for an effective screening hundreds of genes potentially interesting new synthetic lethal targets to discover cancer drugs. Once established, we will find with this combinatorial approach shRNA screening use the bank synthetic targets deadly in any form of cancer models, including prostate tumors and leukemic cell lines, with a set of genes. “

completion of the project, expected to synthetic lethality Cellect tract for a unique collection of isogenic strains from patient breast cancer cells by our staff, Dr. Sun Peiqing at the Scripps Research Institute provided derived built (TSRI). The models will be directly testable in animal models of ex vivo mouse xenographical for clinical effectiveness in monitoring the trials.

This project is part of a series of studies and cooperation Cellect is a worthwhile goal, a database of standard reference gene functional activities and therapeutic targets to develop. The approach for this first project synthetic lethality screening to be used directly applicable to other types of cancer in future studies, such as leukemia and prostate cancer cell lines.


About

Cellect, Inc.

Cellect (www.cellecta.com) is a private research contract, which provides high throughput (HT) RNAi-based genetic tests for the discovery and functional characterization of novel therapeutic targets are available. With its unique platform of lentiviral shRNA, HT sequencing and bioinformatics technologies, they offer the shRNA library screening and sequencing of lentiviral shRNA Libraries HT-pooling and journalists stable overexpression or knockdown cell lines. Cellect scientists have developed some of the most advanced technologies in collaboration with opinion leaders and funded by 11 NIH SBIR grants. For more information, visit www.cellecta.com, call 1-877-938-3910, or e-mail info@cellecta.com.

clear = “all”
Motorized screen